The Latest Breaking News from argenx

Airbnb, which is set to join the S&P 500 on Monday, and DKNG lead a watch list of stocks poised to make moves if the stock market can find its footing.

Argenx is Friday's IBD Stock Of The Day. The biotech stock is climbing the right side of a cup base on enthusiasm for its drug, Vyvgart.

The Chart of the Day belongs to the biotechnology company Argenx (ARGX) . I found the stock by using Barchart's powerful screening functions to find stocks with the highest technical buy signals, highest Weighted Alpha, superior current momentum and having a Trend Seeker buy signal then used the Flipchart feature...

Biohaven is taking the same tact that led to a nearly $12 billion Pfizer buyout with the rest of its pipeline — and BHVN stock has soared.

Upgrades

The U.S. Food and Drug Administration (FDA) has accepted the Menarini Group and Radius Health’s (NASDAQ:RDUS), New Drug Application (NDA) for elacestrant for patients with ER+/HER2- advanced or metastatic breast cancer. The agency has granted Priority Review designation and assigned a target action date of February 17, 2023. Radius Health…

SVB Securities initiated coverage on Argenx SE (NASDAQ:ARGX) with an Outperform rating and a $404 price target. Argenx's Vyvgart (efgartigimod) is a neonatal Fc-Receptor (FcRn) antagonist that selectively reduces IgG levels and has the potential to address numerous IgG-mediated autoimmune diseases.  According to the analyst, Argenx has demonstrated strong early launch execution for Vyvgart…

If history is any guide, there may be good fortune ahead for shares of argenx (NASDAQ:ARGX). A so-called "golden cross" has formed on its chart and, not surprisingly, this could be bullish for the stock.

  argenx (NASDAQ:ARGX) reported its Q1 earnings results on Thursday, May 5, 2022 at 01:00 AM. Here's what investors need to know about the announcement.